Prelude Capital Management’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-15,550
| Closed | -$7K | – | 1487 |
|
|
2024
Q1 | $7K | Hold |
15,550
| – | – | ﹤0.01% | 1164 |
|
|
2023
Q4 | $11.5K | Hold |
15,550
| – | – | ﹤0.01% | 964 |
|
|
2023
Q3 | $13.5K | Hold |
15,550
| – | – | ﹤0.01% | 929 |
|
|
2023
Q2 | $29.1K | Hold |
15,550
| – | – | ﹤0.01% | 882 |
|
|
2023
Q1 | $57.5K | Hold |
15,550
| – | – | ﹤0.01% | 897 |
|
|
2022
Q4 | $59.2K | Hold |
15,550
| – | – | ﹤0.01% | 977 |
|
|
2022
Q3 | $123K | Hold |
15,550
| – | – | ﹤0.01% | 1110 |
|
|
2022
Q2 | $327K | Hold |
15,550
| – | – | 0.01% | 873 |
|
|
2022
Q1 | $585K | Hold |
15,550
| – | – | 0.02% | 624 |
|
|
2021
Q4 | $874K | Hold |
15,550
| – | – | 0.02% | 517 |
|
|
2021
Q3 | $1.12M | Hold |
15,550
| – | – | 0.03% | 366 |
|
|
2021
Q2 | $1.49M | Hold |
15,550
| – | – | 0.04% | 315 |
|
|
2021
Q1 | $2.3M | Hold |
15,550
| – | – | 0.06% | 149 |
|
|
2020
Q4 | $2.17M | Buy |
+15,550
| New | +$2.17M | 0.06% | 108 |
|
|
2017
Q4 | – | Sell |
-3
| Closed | -$1K | – | 1649 |
|
|
2017
Q3 | $1K | Buy |
+3
| New | +$1K | ﹤0.01% | 1438 |
|
|
2014
Q3 | – | Hold |
0
| – | – | – | 2045 |
|
|
2014
Q2 | – | Hold |
0
| – | – | – | 2011 |
|